Research Of Hsa-circ-0015022 As A New Diagnostic Biomarker For Pancreatic Cancer And Its Effect On Biological Behavior Of Pancreatic Cancer Cells

Objective : To investigate the feasibility of hsa-circ-0015022 as a marker for the diagnosis of pancreatic cancer from the perspective of blood and tissue of pancreatic cancer patients.To investigate the effect after overexpression or knockdown of hsa-circ-0015022 on biological behavior of pancreatic cancer cells.Methods:The 30 cases of pancreatic cancer and 30 cases of corresponding adjacent tissues(control group)were selected as tissue samples for the study.The 30 blood samples from pancreatic cancer patients and 30 blood samples from healthy volunteers(control group)were selected as blood samples for the study.The tissue samples and blood samples originated from different patients.The expression of hsa-circ-0015022 was determined by Real-time fluorescent quantitative polymerase chain reaction.The clinicopathological data were used to analyze the correlation between this index and age,gender,tumor diameter,serum CEA level,clinical stage,tumor node metastasis(TNM)stage,vascular invasion and lymphatic invasion of pancreatic cancer patients.Combined with CA19-9 whether hsa-circ-0015022 could be used as a biomarker for the diagnosis of pancreatic cancer.The primary pancreatic cancer cell line Capan-2 and the pancreatic cancer metastatic cell line SW1990 were selected as the research objects.In both cell lines,hsa-circ-0015022 was overexpressed and knocked down.Then changes were observed in the biological behavior of cell proliferation,invasion and migration by cck8,Transwell and scratch experiments.Results:1.Compared with the control group,respectively,hsa-circ-0015022 was highly expressed in pancreatic cancer tissues and blood of pancreatic cancer patients(P <0.05).2.The clinicopathological analysis of the tissue samples showed that the expression of hsa-circ-0015022 was related to clinical staging,N staging in TNM staging and lymphatic invasion(P <0.05).The clinicopathological analysis of blood samples showed that the expression of hsa-circ-0015022 was related to the N stage of TNM stage and the serum CA19-9 level(P <0.05).3.Diagnostic efficiency of hsa-circ-0015022 alone: subject operating characteristic curve(ROC)area 0.70,threshold 10.17,sensitivity 0.6230,specificity 0.7097.Diagnostic efficiency of hsa-circ-0015022 combined with CA19-9: area under the ROC curve increased to 0.85,sensitivity increased to 0.7705,and specificity increased to 0.8387.4.In Capan-2 and SW1990 cell lines,cell proliferation increased after overexpression of hsa-circ-0015022 and cell proliferation decreased after knockdown of hsa-circ-0015022(P<0.01).5.In Capan-2 cell line,cell invasion increased after overexpression of hsa-circ-0015022(P<0.05)and cell invasion decreased after knockdown of hsa-circ-0015022(P<0.01).In SW1990 cell line,cell invasion increased after overexpression of hsa-circ-0015022 and cell invasion decreased after knockdown of hsa-circ-0015022(P<0.01).6.In Capan-2 and SW1990 cell lines,cell migration increased after overexpression of hsa-circ-0015022 and cell migration decreased after knockdown of hsa-circ-0015022(P <0.01).Conclusion:The high expression of hsa-circ-0015022 is found in pancreatic cancer tissues and blood of pancreatic cancer patients,and may be related to the N stage of TNM stage.The hsa-circ-0015022 may be used in combination with CA19-9 as a biomarker to assist in the diagnosis of pancreatic cancer,especially the N staging of pancreatic cancer.Overexpression of hsa-circ-0015022 increases the proliferation,invasion,and migration of pancreatic cancer cells,which may promote pancreatic cancer in the development of pancreatic cancer.Inhibition of hsa-circ-0015022 reduces the above biological behavior of pancreatic cancer cells and may become a potential target for the treatment of pancreatic cancer.